532 related articles for article (PubMed ID: 27472037)
1. Do 18F-FDG PET/CT findings have a relationship with histopathological and immunohistochemical factors of breast cancer in men?
Vatankulu B; Işik G; Kocael P; Kuyumcu S; Ilvan Ş; Sağer S; Halaç M; Türkmen C; Sönmezoğlu K
Nucl Med Commun; 2016 Dec; 37(12):1273-1281. PubMed ID: 27472037
[TBL] [Abstract][Full Text] [Related]
2. Prediction of breast cancer recurrence using lymph node metabolic and volumetric parameters from
Kim YI; Kim YJ; Paeng JC; Cheon GJ; Lee DS; Chung JK; Kang KW
Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1787-1795. PubMed ID: 28616695
[TBL] [Abstract][Full Text] [Related]
3. An Investigation of the Relationship Between
Kandemir O; Demir F
Curr Radiopharm; 2024; 17(1):111-116. PubMed ID: 37644744
[TBL] [Abstract][Full Text] [Related]
4. [The relationship between (18)F-FDG PET/CT metabolic parameters and clinicopathological features of breast cancer].
Tang B; Zhang Y; Zhou J; Xu Y; Li TR; Ding CY
Zhonghua Zhong Liu Za Zhi; 2017 Apr; 39(4):280-285. PubMed ID: 28550668
[No Abstract] [Full Text] [Related]
5. Metabolic Tumor Volume on 18F-FDG PET/CT Improves Preoperative Identification of High-Risk Endometrial Carcinoma Patients.
Husby JA; Reitan BC; Biermann M; Trovik J; Bjørge L; Magnussen IJ; Salvesen ØO; Salvesen HB; Haldorsen IS
J Nucl Med; 2015 Aug; 56(8):1191-8. PubMed ID: 26045311
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of metabolic tumour volume and total lesion glycolysis in
Jiménez-Ballvé A; García García-Esquinas M; Salsidua-Arroyo O; Serrano-Palacio A; García-Sáenz JA; Ortega Candil A; Fuentes Ferrer ME; Rodríguez Rey C; Román-Santamaría JM; Moreno F; Carreras-Delgado JL
Rev Esp Med Nucl Imagen Mol; 2016; 35(6):365-372. PubMed ID: 26948652
[TBL] [Abstract][Full Text] [Related]
7. Whole-Body Metabolic Tumor Volume, as Determined by (18)F-FDG PET/CT, as a Prognostic Factor of Outcome for Patients With Breast Cancer Who Have Distant Metastasis.
Son SH; Lee SW; Jeong SY; Song BI; Chae YS; Ahn BC; Lee J
AJR Am J Roentgenol; 2015 Oct; 205(4):878-85. PubMed ID: 26204115
[TBL] [Abstract][Full Text] [Related]
8. PET/CT in breast cancer staging is useful for evaluation of axillary lymph node and distant metastases.
Davidson T; Shehade N; Nissan E; Sklair-Levy M; Ben-Haim S; Barshack I; Zippel D; Halevy A; Chikman B
Surg Oncol; 2021 Sep; 38():101567. PubMed ID: 33866190
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
10. Determination of regional lymph node status using (18)F-FDG PET/CT parameters in oesophageal cancer patients: comparison of SUV, volumetric parameters and intratumoral heterogeneity.
Kim SJ; Pak K; Chang S
Br J Radiol; 2016; 89(1058):20150673. PubMed ID: 26607643
[TBL] [Abstract][Full Text] [Related]
11. Accuracy of F-18 FDG PET/CT with optimal cut-offs of maximum standardized uptake value according to size for diagnosis of regional lymph node metastasis in patients with rectal cancer.
Bae SU; Won KS; Song BI; Jeong WK; Baek SK; Kim HW
Cancer Imaging; 2018 Sep; 18(1):32. PubMed ID: 30217167
[TBL] [Abstract][Full Text] [Related]
12. The Role of 18F-FDG PET/CT in staging of gallbladder carcinomas.
Arslan E; Aksoy T; Dursun N; Gürsu RU; Sevinç MM; Çermik TF
Turk J Gastroenterol; 2020 Feb; 31(2):105-112. PubMed ID: 32141818
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the Usefulness of FDG-PET/CT for Nodal Staging of Breast Cancer.
Orsaria P; Chiaravalloti A; Caredda E; Marchese PV; Titka B; Anemona L; Portarena I; Schillaci O; Petrella G; Palombi L; Buonomo OC
Anticancer Res; 2018 Dec; 38(12):6639-6652. PubMed ID: 30504372
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of FDG PET/CT derived parameters in prediction of histopathological finding during the surgery in patients with pancreatic adenocarcinoma.
Myssayev A; Myssayev A; Ideguchi R; Eguchi S; Adachi T; Sumida Y; Tobinaga S; Uetani M; Kudo T
PLoS One; 2019; 14(1):e0210178. PubMed ID: 30629646
[TBL] [Abstract][Full Text] [Related]
15.
Mantziari S; Pomoni A; Prior JO; Winiker M; Allemann P; Demartines N; Schäfer M
BMC Med Imaging; 2020 Jan; 20(1):7. PubMed ID: 31969127
[TBL] [Abstract][Full Text] [Related]
16. Nasopharyngeal carcinoma: relationship between 18F-FDG PET-CT maximum standardized uptake value, metabolic tumour volume and total lesion glycolysis and TNM classification.
Chan WK; Mak HK; Huang B; Yeung DW; Kwong DL; Khong PL
Nucl Med Commun; 2010 Mar; 31(3):206-10. PubMed ID: 19966594
[TBL] [Abstract][Full Text] [Related]
17. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer.
Ulaner GA; Castillo R; Goldman DA; Wills J; Riedl CC; Pinker-Domenig K; Jochelson MS; Gönen M
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1937-44. PubMed ID: 27129866
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of
Jung JH; Lee SW; Son SH; Kim CY; Lee CH; Jeong JH; Jeong SY; Ahn BC; Lee J
Head Neck; 2017 Mar; 39(3):447-455. PubMed ID: 27726225
[TBL] [Abstract][Full Text] [Related]
19. Prediction of Recurrence and Mortality of Locally Advanced Esophageal Cancer Patients Using Pretreatment F-18 FDG PET/CT Parameters: Intratumoral Heterogeneity, SUV, and Volumetric Parameters.
Chang S; Kim SJ
Cancer Biother Radiopharm; 2016 Feb; 31(1):1-6. PubMed ID: 26844846
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of Percentage Change in Metabolic Parameters as Measured by Dual-Time Point
Yoo J; Yoon HJ; Kim BS
J Womens Health (Larchmt); 2017 Oct; 26(10):1131-1137. PubMed ID: 28498790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]